Patents by Inventor Andrew Stewart Tasker

Andrew Stewart Tasker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF
    Publication number: 20250179013
    Abstract: Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
    Type: Application
    Filed: February 17, 2023
    Publication date: June 5, 2025
    Inventors: Matthew H. Daniels, Kenneth W. Duncan, Brian Andrew Sparling, Young-tae Lee, Jennifer Castro, Scott Ribich, Ernest Allen Sickmier, Andrew Stewart Tasker, James Edward John Mills
  • SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE
    Publication number: 20250154109
    Abstract: The invention provides compounds that are useful for treatment of conditions associated with aberrant activity of voltage gated sodium channel Nav1.8, and methods of treating a subject with those compounds for conditions such as pain, itch, and cough.
    Type: Application
    Filed: February 2, 2023
    Publication date: May 15, 2025
    Inventors: Ashok Bajji, Michael D. Kaufman, Bryan Moyer, James Michael Balkovec, Andrew Stewart Tasker
  • INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF
    Publication number: 20250145597
    Abstract: Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
    Type: Application
    Filed: October 23, 2024
    Publication date: May 8, 2025
    Inventors: Matthew H. Daniels, Kenneth W. Duncan, Brian Andrew Sparling, Young-tae Lee, Jennifer Castro, Scott Ribich, Ernest Allen Sickmier, Andrew Stewart Tasker, James Edward John Mills, Gavin Whitlock, Andrew J. Jennings
  • Inhibitors of RNA helicase DHX9 and uses thereof
    Patent number: 12233065
    Abstract: Provided are compounds of the Formula (IVB): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
    Type: Grant
    Filed: March 28, 2024
    Date of Patent: February 25, 2025
    Assignee: ACCENT THERAPEUTICS, INC.
    Inventors: Matthew H. Daniels, Kenneth W. Duncan, Brian Andrew Sparling, Andrew Stewart Tasker, Gavin Whitlock
  • Inhibitors of RNA helicase DHX9 and uses thereof
    Patent number: 12162867
    Abstract: Provided are compounds of the Formula (IIB): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
    Type: Grant
    Filed: March 28, 2024
    Date of Patent: December 10, 2024
    Assignee: ACCENT THERAPEUTICS, INC.
    Inventors: Matthew H. Daniels, Kenneth W. Duncan, Brian Andrew Sparling, Andrew Stewart Tasker, Gavin Whitlock
  • Substituted pyridine derivatives as SARM1 inhibitors
    Patent number: 12110285
    Abstract: This disclosure is drawn to pyridine derivatives, compositions thereof, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological disorders.
    Type: Grant
    Filed: March 3, 2023
    Date of Patent: October 8, 2024
    Assignee: NURA BIO, INC.
    Inventors: Rao Kolluri, Christopher Michael Tegley, Liusheng Zhu, Sean Pomeroy Brown, Charles Howard Reynolds, Andrew Stewart Tasker, Cheryl A. Grice
  • INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF
    Publication number: 20240316047
    Abstract: Provided are compounds of the Formula (IVB): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
    Type: Application
    Filed: March 28, 2024
    Publication date: September 26, 2024
    Inventors: Matthew H. Daniels, Kenneth W. Duncan, Brian Andrew Sparling, Andrew Stewart Tasker, Gavin Whitlock
  • INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF
    Publication number: 20240279210
    Abstract: Provided are compounds of the Formula (IIB): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
    Type: Application
    Filed: March 28, 2024
    Publication date: August 22, 2024
    Inventors: Matthew H. Daniels, Kenneth W. Duncan, Brian Andrew Sparling, Andrew Stewart Tasker, Gavin Whitlock
  • METTL3 MODULATORS
    Publication number: 20240051985
    Abstract: Provided are compounds of Formula (I?) or (I) below, or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: October 13, 2021
    Publication date: February 15, 2024
    Inventors: Matthew H. Daniels, Thomas Andrew Wynn, Brian Andrew Sparling, Ernest Allen Sickmier, Andrew Stewart Tasker, James Edward John Mills
  • 4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE SUMO INHIBITORS AND USES THEREOF
    Publication number: 20230303584
    Abstract: The present invention relates to compounds and compositions capable of acting as inhibitors of small ubiquitin-like modifier (SUMO) family of proteins. The compounds and compositions may be used in the treatment of cancer. There are disclosed, inter alia, methods of inhibiting an E1 enzyme, and compounds useful for inhibiting an E1 enzyme.
    Type: Application
    Filed: January 22, 2021
    Publication date: September 28, 2023
    Inventors: Xiaohu Ouyang, Miles Douglas Kubota, Andrew Stewart Tasker, Fang-Tsao Hong, Mary Walton, Victor J. Cee
  • SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
    Publication number: 20230286941
    Abstract: This disclosure is drawn to pyridine derivatives, compositions thereof, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological disorders.
    Type: Application
    Filed: March 3, 2023
    Publication date: September 14, 2023
    Inventors: Rao KOLLURI, Christopher Michael TEGLEY, Liusheng ZHU, Sean Pomeroy BROWN, Charles Howard REYNOLDS, Andrew Stewart TASKER, Cheryl A. GRICE
  • Substituted pyridine derivatives as SARM1 inhibitors
    Patent number: 11629136
    Abstract: This disclosure is drawn to pyridine derivatives, compositions thereof, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological disorders.
    Type: Grant
    Filed: July 27, 2022
    Date of Patent: April 18, 2023
    Assignee: NURA BIO, INC.
    Inventors: Rao Kolluri, Christopher Michael Tegley, Liusheng Zhu, Sean Pomeroy Brown, Charles Howard Reynolds, Andrew Stewart Tasker, Cheryl A. Grice
  • SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
    Publication number: 20230105696
    Abstract: This disclosure is drawn to pyridine derivatives, compositions thereof, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological disorders.
    Type: Application
    Filed: July 27, 2022
    Publication date: April 6, 2023
    Inventors: Rao KOLLURI, Christopher Michael TEGLEY, Liusheng ZHU, Sean Pomeroy BROWN, Charles Howard REYNOLDS, Andrew Stewart TASKER, Cheryl A. GRICE
  • METTL3 MODULATORS
    Publication number: 20230027361
    Abstract: Provided are compounds of Formula (I?) or (II?), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: October 20, 2020
    Publication date: January 26, 2023
    Applicant: Accent Therapeutics, Inc.
    Inventors: Thomas Andrew Wynn, Brian Lewis Hodous, Paula Ann Boriack-Sjodin, Ernest Allen Sickmier, James Edward John Mills, Robert A. Copeland, Andrew Stewart Tasker, Matthew H. Daniels, Kenneth W. Duncan, Brian Andrew Sparling
  • METTL3 MODULATORS
    Publication number: 20220372040
    Abstract: Provided are compounds of Formula (I?) or (I) below, or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: October 22, 2020
    Publication date: November 24, 2022
    Applicants: Accent Therapeutics, Inc., Accent Therapeutics, Inc.
    Inventors: Thomas Andrew Wynn, Brian Lewis Hodous, Paula Ann Boriack-Sjodin, Ernest Allen Sickmier, James Edward John Mills, Andrew Stewart Tasker, Robert A. Copeland